WUXI, China, Dec. 6, 2017 /PRNewswire/ — WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company, offering end-to-end solutions for biologics discovery, development and manufacturing, today announced that its cGMP biologics manufacturing facility in…